Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

(2021) Raches Ella et al.   LANCET INFECTIOUS DISEASES

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2021) Zhiwei Wu et al.   LANCET INFECTIOUS DISEASES

Inactivated COVID-19 vaccines to make a global impact

(2021) Patrick L Iversen et al.   LANCET INFECTIOUS DISEASES

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

(2021) Chadi M. Saad-Roy et al.   SCIENCE

Th1 Skewed immune response of Whole Virion Inactivated SARS CoV 2 Vaccine and its safety evaluation

(2021) Brunda Ganneru et al.   iScience

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model

(2021) Sreelekshmy Mohandas et al.   iScience

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

(2021) William N. Voss et al.   SCIENCE

A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial

(2021) Murat Akova et al.   Trials

COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials

(2021) Zhi-Peng Yan et al.   Pharmaceuticals

Functional responsiveness of memory T cells from COVID-19 patients

(2021) Ece Tavukcuoglu et al.   CELLULAR IMMUNOLOGY

The psychological impact of quarantine and how to reduce it: rapid review of the evidence

(2020) Samantha K Brooks et al.   LANCET

COVID-19 exacerbating inequalities in the US

(2020) Aaron van Dorn et al.   LANCET

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

(2020) Hui Wang et al.   CELL

A minimal common outcome measure set for COVID-19 clinical research

(2020) John C Marshall et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2 vaccines in development

(2020) Florian Krammer   NATURE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES